Editas Medicine (EDIT) Goodwill & Intangibles (2020)

Editas Medicine (EDIT) reported Goodwill & Intangibles of $5.0 million for Q4 2020, little changed on a QoQ basis from $5.0 million in Q3 2020.

Editas Medicine (EDIT) has 1 years of Goodwill & Intangibles data on file, last reported at $5.0 million in Q4 2020.

  • Quarterly Goodwill & Intangibles changed N/A year-over-year to $5.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $5.0 million (changed N/A YoY) and the FY2020 annual result came in at $5.0 million, changed N/A from the prior year.
  • Goodwill & Intangibles steadied at $5.0 million in Q4 2020 per EDIT's latest filing, from $5.0 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $5.0 million in Q3 2020 and bottomed at $5.0 million in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Editas Medicine 338.62 Mn 338.62 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 5.00 Mn
Sep 30, 2020 5.00 Mn